dc.contributor.author |
Gorgel, Ahmet |
|
dc.contributor.author |
Tecellioglu, Mehmet |
|
dc.contributor.author |
Cankaya, Cem |
|
dc.date.accessioned |
2022-03-08T09:49:57Z |
|
dc.date.available |
2022-03-08T09:49:57Z |
|
dc.date.issued |
2019 |
|
dc.identifier.citation |
Gorgel, A., Tecellioglu, M., & Cankaya, C. (2021). Autoimmune polyglandular syndrome type III which accompanies to multiple sclerosis: A case report . Annals of Medical Research |
en_US |
dc.identifier.uri |
http://hdl.handle.net/11616/54742 |
|
dc.description.abstract |
Autoimmune polyglandular syndrome type III (APS III) is characterised by autoimmune destruction of various endocrine and nonendocrine tissues. It differs from APS I and APS II in terms of without adrenal involvement. Although APS III includes a series of
autoimmune disorders, it is rarely associated with multiple sclerosis (MS). A 41-year-old female patient had diplopia, visual blurring,
dizziness, and giddiness for 2 weeks. In her medical history, she had a diagnosis of MS and using Teriflunomide. It was detected
positivity of antinuclear antibody (ANA), anti-thyroid peroxidase (Anti-TPO) and anti-thyroglobulin (Anti-TG) antibodies. Based on
these results, the patient with MS who has chronic autoimmune thyroiditis and primary ovarian failure was diagnosed with APS
III. The coexistence of APS-III and MS is a rare clinical entity. Moreover, hypothyroidism has been detected during teriflunomide
therapy in the patient. Hypothyroidism was most likely a component of APS-III in our case, but it may also have been triggered by
teriflunomide. |
en_US |
dc.language.iso |
eng |
en_US |
dc.rights |
info:eu-repo/semantics/openAccess |
en_US |
dc.title |
Autoimmune polyglandular syndrome type III which accompanies to multiple sclerosis: A case report |
en_US |
dc.type |
article |
en_US |
dc.relation.journal |
Annals of Medical Research |
en_US |
dc.contributor.department |
İnönü Üniversitesi |
en_US |